Factors attributed to non-adherence of treatment among Tuberculosis patients registered in Jamnagar district, Gujarat

Shah, Viral N.; Pithadia, Pradeep; Parmar, Dipesh; Chavda, Bharat

doi:10.5455/jrmds.2016437

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 The overall pooled estimated prevalence for the Asia region was 17% (95% CI 16% to 18%). The highest pooled prevalence was noted in Southern Asia (22% (95% CI 16% to 29%)), [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] followed by Eastern Asia (18% (95% CI 16% to 20%)), [43][44][45][46][47][48][49][50][51][52][53][54][55] South East Asia (16% (95% 4% to 28%)), [56][57][58][59][60][61] Western Asia (10% (95% 5% to 15%)) [62][63][64] and Central Asia (6% (95% CI 5% to 7%)). 65 66 (figure 2) Subgroup analysis based on the duration of treatment interruption (36 studies, excluded non-defined duration of treatment interruption), demonstrated the pooled prevalence for ≥2 months interruption was 10% (95% CI 9% to 11%), which was much lower than another subgroup that considered the minimum duration of <2 months, 28% (95% CI 20% to 36%) (online supplemental figure S1).…”

Section: Prevalence Of Tb Treatment Interruptionmentioning

confidence: 99%

Prevalence and predictive factors of tuberculosis treatment interruption in the Asia region: a systematic review and meta-analysis

Makmor-Bakry

Islahudin

et al. 2023

BMJ Glob Health

View full text Add to dashboard Cite

IntroductionTuberculosis (TB) treatment interruption remains a critical challenge leading to poor treatment outcomes. Two-thirds of global new TB cases are mostly contributed by Asian countries, prompting systematic analysis of predictors for treatment interruption due to the variable findings.MethodsArticles published from 2012 to 2021 were searched through seven databases. Studies that established the relationship for risk factors of TB treatment interruption among adult Asian were included. Relevant articles were screened, extracted and appraised using Joanna Briggs Institute’s checklists for cohort, case–control and cross-sectional study designs by three reviewers. Meta-analysis was performed using the random effect model in Review Manager software. The pooled prevalence and predictors of treatment interruption were expressed in ORs with 95% CIs; heterogeneity was assessed using the I2statistic. The publication bias was visually inspected using the funnel plot.ResultsFifty eligible studies (658 304 participants) from 17 Asian countries were included. The overall pooled prevalence of treatment interruption was 17% (95% CI 16% to 18%), the highest in Southern Asia (22% (95% CI 16% to 29%)), followed by Eastern Asia (18% (95% CI 16% to 20%)) and South East Asia (16% (95% CI 4% to 28%)). Seven predictors were identified to increase the risk of treatment interruption, namely, male gender (OR 1.38 (95% CI 1.26 to 1.51)), employment (OR 1.43 (95% CI 1.11 to 1.84)), alcohol intake (OR 2.24 (95% CI 1.58 to 3.18)), smoking (OR 2.74 (95% CI 1.98 to 3.78)), HIV-positive (OR 1.50 (95% CI 1.15 to 1.96)), adverse drug reactions (OR 2.01 (95% CI 1.20 to 3.34)) and previously treated cases (OR 1.77 (95% CI 1.39 to 2.26)). All predictors demonstrated substantial heterogeneity except employment and HIV status with no publication bias.ConclusionThe identification of predictors for TB treatment interruption enables strategised planning and collective intervention to be targeted at the high-risk groups to strengthen TB care and control in the Asia region.

show abstract